{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-078108","form_type":"8-K","ticker":"ATXI","cik":"0001644963","company_name":"AVENUE THERAPEUTICS, INC.","filed_at":"2023-07-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.665443+00:00","generated_at":"2026-06-13T12:42:11.934495+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Avenue Therapeutics grants options for 1.05M shares to CEO and Interim CFO","bullets":["CEO Alexandra MacLean granted option to purchase 800,000 shares at $1.14/share.","Interim CFO/COO David Jin granted option to purchase 250,000 shares at same price.","Options vest in four equal annual installments beginning August 1, 2023.","Options expire 10 years from grant dates (June 29, 2033 and June 30, 2033)."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-078108","json":"https://secwatch.observer/filing/0001104659-23-078108.json","markdown":"https://secwatch.observer/filing/0001104659-23-078108.md","text":"https://secwatch.observer/filing/0001104659-23-078108.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1644963/000110465923078108/0001104659-23-078108-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1644963/000110465923078108/tm2320616d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T12:42:11.934495+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}